Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 7, 2016

Primary Completion Date

February 15, 2017

Study Completion Date

March 15, 2017

Conditions
Breast Cancer
Interventions
DRUG

Pegfilgrastim

A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).

DRUG

Doxorubicin/Cyclophosphamide(AC) treatment

"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."

Trial Locations (1)

03722

Division of Medical Oncology, Severance Breast Cancer Clinic, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03575520 - Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients | Biotech Hunter | Biotech Hunter